Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 13,100 shares, a growth of 67.9% from the January 15th total of 7,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 66,100 shares, the short-interest ratio is presently 0.2 days.

Evogene Stock Performance

Shares of NASDAQ EVGN traded up $0.07 during trading on Friday, hitting $1.55. 10,024 shares of the company traded hands, compared to its average volume of 27,162. The business’s fifty day moving average is $1.57 and its 200 day moving average is $2.37. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.40. The firm has a market capitalization of $8.31 million, a price-to-earnings ratio of -0.35 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.40% of Evogene at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Evogene in a report on Friday. They set a “sell” rating on the stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.